ENvue Medical Adds to Intellectual Property Portfolio by Securing USPTO Notice of Allowance for Ultrasound-Enhanced Cannabinoid Drug Delivery Technology
Rhea-AI Summary
ENvue Medical (NASDAQ: FEED) received a USPTO Notice of Allowance for U.S. Patent Application No. 17/025,969 on May 8, 2026, covering a surface acoustic wave (SAW) ultrasound-enhanced system for transdermal delivery of cannabinoid therapeutics.
The allowed claims span transdermal patch configurations, portable SAW-generating platforms, and methods that the company says produce synergistic enhancement of cannabinoid skin absorption versus patch-only administration. The company says the allowance broadens its IP footprint and could enable future collaborations and applications beyond existing marketed products.
Positive
- USPTO Notice of Allowance for SAW-enhanced cannabinoid transdermal delivery
- Broad claim scope covering patches, portable SAW platforms, and delivery methods
- Extends SAW platform into therapeutic drug-delivery applications beyond feeding tubes
Negative
- No commercialization timeline or revenue guidance disclosed for the patented technology
News Market Reaction – FEED
In the May 8 session, FEED declined 9.85%, reflecting a notable negative market reaction. Argus tracked a peak move of +10.9% during that session. Argus tracked a trough of -15.9% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. Trading volume was elevated at 2.5x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Purchasing agreement renewal | Positive | +5.6% | Three-year GPO purchasing agreement renewal covering a large U.S. health system. |
| Apr 20 | New hospital customer | Positive | -4.4% | 40th U.S. hospital adoption of ENvue Navigation Platform at a 255-bed medical center. |
| Apr 16 | Stockholder letter update | Positive | -7.5% | Corporate update on 39 U.S. hospitals, recurring revenue, and new patent allowance. |
| Mar 24 | Hospital footprint expansion | Positive | +58.0% | Purchase expanding footprint to 39 hospitals including a 714-bed trauma center in Michigan. |
| Feb 24 | Patent portfolio expansion | Positive | +5.6% | USPTO Notice of Allowance for feeding tube with electromagnetic sensor and camera. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive commercial or patent news has often led to price gains, including a 58.04% jump on a March hospital footprint expansion, but there are also instances of negative reactions to positive updates.
Over the past several months, ENvue reported multiple commercial wins and IP milestones. It expanded its U.S. hospital footprint to 39–40 hospitals, renewed a three-year purchasing agreement with a large health system operating over 90 hospitals through 2028, and received a February USPTO Notice of Allowance for a feeding tube with an integrated camera. A March footprint expansion coincided with a 58.04% move, while other positive updates saw mixed reactions. Today’s cannabinoid-focused patent allowance adds another dimension to this IP build-out.
Key Terms
notice of allowance regulatory
surface acoustic wave medical
transdermal medical
cannabinoid-based therapeutics medical
uspto regulatory
510(k) cleared regulatory
schedule 13d/a regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Patent Expands Company's Proprietary Surface Acoustic Wave Platform into Advanced Therapeutic Delivery Applications
TYLER, Texas, May 08, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) ("ENvue," "ENvue Medical" or the "Company"), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/025,969, covering a novel drug delivery system utilizing the Company's proprietary surface acoustic wave (SAW) technology to enhance transdermal delivery of cannabinoid-based therapeutics.
The allowed claims provide broad intellectual property protection across multiple components of the combined SAW ultrasound and cannabinoid transdermal delivery system, including transdermal patch configurations, portable SAW-generating platforms, and methods shown to produce synergistic enhancement in cannabinoid absorption through the skin compared to administration via the transdermal patch alone.
Cannabinoid-based therapeutics continue to attract growing scientific, pharmaceutical, and commercial interest globally, particularly in pain management, neurology, inflammation, and chronic disease applications. ENvue Medical believes its ultrasound-based delivery platform may provide future opportunities to improve therapeutic administration and enable strategic collaborations across multiple treatment categories.
"This Notice of Allowance validates a meaningful expansion of our SAW platform into an entirely new therapeutic category,” said Doron Besser, MD, Chief Executive Officer of ENvue Medical. “We believe that the USPTO's recognition of the synergistic effect between our ultrasound technology and cannabinoid transdermal delivery, and its determination that this combination was non-obvious, reflects the depth and breadth of our intellectual property portfolio. We believe this positions ENvue favorably as interest in cannabinoid-based therapeutics continues to grow, and we look forward to exploring the strategic opportunities this patent creates for the Company."
The Company believes this patent allowance further reinforces the value and versatility of its proprietary SAW technology platform and highlights the potential for future applications beyond its currently marketed products.
About ENvue Medical, Inc.
ENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Tel-Aviv and Nesher, Israel, the Company focuses on two distinct technology platforms:
- ENvue™ Navigation Platform, developed and operated by ENvue Medical Inc., with offices in Arlington Heights, Illinois, and Tel-Aviv, Israel, is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. FDA 510(k) cleared for adult use, ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Future platform expansion may include pediatric and vascular access applications.
- ENvue Medical aims to advance standards in non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation across a range of healthcare environments.
- Acoustic-based therapeutic technologies, including PainShield® and UroShield®, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms.
Forward-Looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. These forward-looking statements include, but are not limited to: statements regarding the adoption and implementation of ENvue Medical’s platforms, anticipated commercial expansion, growth, scalability, and implementation of ENvue Medical’s products, the success of ENvue’s programs, market interest in the Company’s technology, and future expectations for strategic growth. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: (i) market acceptance of the Company’s existing and new products; (ii) clinical performance and operational outcomes; (iii) delays or complications in product implementation; (iv) intense competition in the medical device industry; (v) product liability or performance issues; (vi) limitations in manufacturing or supply chain capabilities; (vii) reimbursement limitations; (viii) intellectual property protection; (ix) healthcare regulatory changes in the U.S. and abroad; and (x) the need for additional capital. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge at: www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.
Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
PH: (212) 896-1254
envue@kcsa.com
Media Contact:
KCSA Strategic Communications
Michaela Fawcett, Senior Account Director
PH: (978) 995-4683
envue@kcsa.com
